Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Leder, Kevin ^a   Foo, Jasmine ^a   Skaggs, Brian ^b   Gorre, Mercedes ^c   Sawyers, Charles L ^d   Michor, Franziska ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Combimatrix ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EARLY DIAGNOSIS; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR CLONING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT OUTCOME; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; MUTATION; MUTATION RATE; PROTEIN TERTIARY STRUCTURE; REPRODUCTIVE FITNESS; RISK FACTOR; TIME;

CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENETIC FITNESS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; MUTATION RATE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; RISK FACTORS; TIME FACTORS;

EID: 82155181972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027682     Document Type: Article

References (42)

1. Shtivelman E, Lifshitz B, Gale R, Canaani E, (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315: 550-554.
2. Nowell P, (1960) Phytohemagglutnin: An initiator of mitosis in cultures of normal human leukocytes. Cancer Research 20: 462-466.
3. Goldman J, Melo J, (2003) Chronic myeloid leukemia advances in biology and new approaches to treatment. New England Journal of Medicine 349: 1451-1464.
4. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 344: 1031-1037.
5. Hochhaus A, (2006) Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors. Annals of Oncology 17: 274-279.
6. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 348: 994-1004.
7. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
8. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, et al. (2006) Phosphorylation of the ATP-binding loop directs oncogeneticity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103: 19466-19471.
9. Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (sti571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
10. Gambacorti-Passerini C, Gunby R, Piazza R, Galietta A, Rostagno R, et al. (2003) Molecular mechanisms of resistance to imatinib in philadelphia-chromosome-positive leukaemias. The Lancet Oncology 4: 75-85.
11. Hochhaus A, Rosee PL, (2004) Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18: 1321-1331.
12. Quintas-Cardama A, Kantajian H, Cortes J, (2007) Flying under the radar: the new wave of BCRABL inhibitors. Nature Reviews Drug Discovery 6: 834-848.
13. Gibbons D, Pricl S, Kantarjian H, Cortes J, Quintas-Cardama A, (2011) The rise and fall of gatekeeper mutations? the BCR-ABL1 T315I paradigm. Cancer To Appear.
14. Chanock S, Thomas G, (2007) The devil is in the DNA. Nature Genetics 39: 283-284.
15. Luria S, Delbruck M, (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28: 491-511.
16. Coldman A, Goldie J, (1986) A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 48: 279-292.
17. Angerer W, (2001) An explicit representation of the Luria-Delbrück distribution. Journal of Mathematical Biology 42: 145-174.
18. Dewanji A, Luebeck E, Moolgavkar S, (2005) A generalized Luria-Delbrück model. Mathematical Biosciences 197: 140-152.
19. Iwasa Y, Nowak M, Michor F, (2006) Evolution of resistance during clonal expansion. Genetics 172: 2557-2566.
20. Frank S, (2003) Somatic mosaicism and cancer: inference based on a conditional Luria-Delbruck distribution. Journal of Theoretical Biology 223: 405-412.
21. Haeno H, Iwasa Y, Michor F, (2007) The evolution of two mutations during clonal expansion. Genetics 177: 2209-2221.
22. Harnevo L, Agur Z, (1992) Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemotherapy Pharmacology 30: 469-476.
23. Komarova N, Wodarz D, (2005) Drug resistance in cancer: Principles of emergence and prevention. PNAS 102: 9714-9719.
24. Komarova N, Wodarz D, (2007) Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theoretical Population biology 72: 523-538.
25. Durrett R, Moseley S, (2010) Evolution of resistance and progression to disease during clonal expansion of cancer. Theoretical Population Biology 77: 42-48.
26. Chmielecki J, Foo J, Oxnard G, Hutchinson K, Ohashi K, et al. (2011) Optimization of dosing for egfr-mutant nonsmall cell lung cancer with evolutionary cancer modeling. Science Translational Med 3: 90ra59.
27. Fokas A, Keller J, Clarkson B, (1991) Mathematical model of granulocytopoiesis and chronic myelogenous leukemia. Cancer Research 51: 2084-2091.
28. Michor F, Iwasa Y, Hughes T, Branford S, Shah N, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435: 1267-1270.
29. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller M, et al. (2006) Dynamic modeling of imatinibtreated chronic myeloid leukemia: functional insights and clinical implications. Nature Medicine 12.
30. Kim P, Lee P, Levy D, (2008) Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull Math Biol 70: 728-744.
31. Kim P, Lee P, Levy D, (2008) A PDE model for imatinib-treated chronic myelogenous leukemia. Bull Math Biol 70: 1994-2016.
32. Foo J, Drummond M, Clarkson B, Holyoake T, Clarkson B, et al. (2009) Eradication of chronic myeloid leukemia stem cells: A novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Computational Biology pp. e10000503.
33. Komarova N, (2006) Stochastic modeling of drug resistance in cancer. Journal of Theoretical Biology 239: 351-366.
34. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarjian H, (2006) The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targ Oncol 1: 186-196.
35. Kunkel T, Bebenek K, (2000) DNA replication fidelity. Annual Review of Biochemistry 69: 497-529.
36. Seshadri R, Kutlaca RJ, Trainor K, Matthews C, Morley A, (1987) Mutation rate of normal and malignant human lymphocytes. Cancer Research 47: 407.
37. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, et al. (2006) BCR/ABL kinase induces selfmutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108: 319-327.
38. Holyoake T, Jiang X, Eaves C, Eaves A, (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064.
39. Graham S, Jorgensen H, Allan E, Pearson C, Alcorn M, et al. (2002) Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to sti571 in vitro. Blood 99: 319-325.
40. Ichimaru M, Tomonaga M, Amenomori T, Matsuo T, (1991) Atomic bomb and leukemia. Journal of Radiation Research 32: 14-19.
41. Magurran A, (2004) Measuring Biological Diversity. Blackwell.
42. Pierce A, Spooncer E, Ainsworth S, Whetton AD, (2002) BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene 21.